Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
17.44
0.00 (0.00%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Amneal Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 3,118 | 3,019 | 2,794 | 2,394 | 2,212 | 2,094 |
Revenue Growth | 9.28% | 8.05% | 16.73% | 8.20% | 5.67% | 5.08% |
Gross Profit Gross Profit Growth | 1,241 | 1,128 | 1,016 | 852.87 | 791.46 | 783.95 |
Operating Income Operating Income Growth | 495.15 | 420.7 | 348.36 | 260.38 | 200.03 | 216.6 |
Net Income Net Income Growth | 157.36 | 72.06 | -116.89 | -83.99 | -129.99 | 10.62 |
Earnings Per Share EPS Growth | 0.48 | 0.22 | -0.38 | -0.48 | -0.86 | 0.07 |
EPS Growth | 4332.00% | - | - | - | - | -88.52% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Affordable Medicines Net Affordable Medicines Net Growth | 1,811 | 1,746 | 1,685 | 1,471 | 1,432 | 1,366 |
Specialty Net Specialty Net Growth | 574.73 | 528.51 | 445.75 | 390.46 | 374.12 | 378.32 |
AvKARE Net AvKARE Net Growth | 732.28 | 744.73 | 662.95 | 531.75 | 406.11 | 349.01 |
Revenue (Total) Revenue (Total) Growth | 3,118 | 3,019 | 2,794 | 2,394 | 2,212 | 2,094 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 131.41 | 286.47 | 112.42 | 93.74 | 27.8 | 248.96 |
Total Debt Total Debt Growth | 2,792 | 2,689 | 2,593 | 2,751 | 2,845 | 2,888 |
Net Cash (Debt) Net Cash Growth | -2,660 | -2,403 | -2,481 | -2,657 | -2,817 | -2,639 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -8.12 | -7.40 | -8.03 | -15.08 | -18.66 | -17.38 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 200.78 | 339.99 | 295.1 | 345.58 | 65.1 | 241.82 |
Capital Expenditures CapEx Growth | -117.67 | -98.84 | -60.34 | -46.8 | -48.8 | -50.94 |
Free Cash Flow Free Cash Flow Growth | 83.11 | 241.15 | 234.76 | 298.78 | 16.3 | 190.88 |
Free Cash Flow Growth | -69.32% | 2.72% | -21.43% | 1732.42% | -91.46% | -39.82% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 39.81% | 37.38% | 36.35% | 35.63% | 35.77% | 37.44% |
Operating Margin | 15.88% | 13.94% | 12.47% | 10.88% | 9.04% | 10.35% |
Pretax Margin | 6.45% | 4.61% | -1.97% | -1.68% | -11.22% | 1.50% |
Profit Margin | 5.05% | 2.39% | -4.18% | -3.51% | -5.88% | 0.51% |
FCF Margin | 2.67% | 7.99% | 8.40% | 12.48% | 0.74% | 9.12% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 36.27 | 54.97 | - | - | - | 67.35 |
Forward PE | 17.58 | 15.04 | 11.69 | 11.92 | 2.71 | 5.65 |
P/FCF Ratio | 73.09 | 16.43 | 10.45 | 6.23 | 18.49 | 3.75 |
PS Ratio | 1.95 | 1.31 | 0.88 | 0.78 | 0.14 | 0.34 |